Halozyme Therapeutics (NASDAQ: HALO) reported Q1 EPS of ($0.26), $0.01 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $29.6 million versus the consensus estimate of $30.85 million.

Financial Outlook for 2017

For 2017, the company reiterated its financial guidance of:

• Net revenue of $115 million to $130 million;
• Operating expenses of $240 million to $250 million;
• Operating cash burn of $75 million to $85 million; and
• Year-end cash balance of $110 million to $125 million.

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.